Stability, blood partition and plasma protein binding of ipriflavone, an isoflavone derivative

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 7, 1999, Pages 355-360

  Kim, So H ^a   Lee, Jung S ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Samchundang Pharm Co Ltd   (South Korea)

Author keywords

Blood partition; Ipriflavone; Protein binding; Stability

Indexed keywords

HUMAN SERUM ALBUMIN; IPRIFLAVONE; PLASMA PROTEIN;

ANIMAL CELL; ARTICLE; BLOOD CELL; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG STABILITY; HUMAN; HUMAN CELL; LIVER HOMOGENATE; NONHUMAN; PH; PLASMA CELL; PLASMA PROTEIN BINDING; RABBIT; RAT; STOMACH JUICE;

ANIMALS; BLOOD CELLS; BLOOD PROTEINS; BONE REMODELING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIALYSIS; GASTRIC JUICE; HEMATOCRIT; HUMANS; HYDROGEN-ION CONCENTRATION; ISOFLAVONES; LIVER; PROTEIN BINDING; RABBITS; RATS; SERUM ALBUMIN;

EID: 0033503657     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199910)20:7<355::AID-BDD197>3.0.CO;2-X     Document Type: Article

References (19)

1. Shin WG, Lee MG, Lee MH, Kim ND. Pharmacokinetics of drugs in blood VII: unusual distribution and blood storage effect of vancomycin. Biopharm Drug Disposit 1992; 13: 305-310.
2. Lee SH, Lee MG. Stability, tissue metabolism, tissue distribution and blood partition of azosemide. Biopharm Drug Disposit 1995; 16: 547-561.
3. Lin JH. Dose-dependent pharmacokinetics: experimental observations and theoretical considerations. Biopharm Drug Disposit 1994; 15: 1-31.
4. Terao N, Shen DD. Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. J Pharmacol Exp Ther 1983; 227: 369-375.
5. Takenaka M, Nakata M, Tsubioi S, Fujita T. Vitamin D, Chemical, Biochemical and Clinical Endocrinology of Calcium Metabolism. Berlin: Walter de Guyter, 1982; 607.
6. Kakai Y, Kawase T, Nakano T, Mikuni-Takagaki Y, Saito S. Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells. Calcif Tissue Int 1992; 51(Suppl 1): 11-15.
7. Reginster J-YL. Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner 1993; 23: 223-232.
8. Shino M. Pharmacokinetic study of ipriflavone (TC80) by oral administration in healthy male volunteers. Jpn Pharmacol Ther 1985; 13: 7223-7233.
9. Rondelli I, Acerbi D, Ventura P. Steady state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure. Int J Clin Pharm Res 1991; 11: 179-185.
10. Rohatagi S, Barrett JS, Sawyers W, Yu K, Morales RJ. Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet. Am J Ther 1997; 1: 229-238.
11. Kim SH, Lee J-S, Lee MG. Determination of an isoflavone derivative, ipriflavone, and its metabolites, M1 and M5, in rat plasma, urine, and tissue homogenate by high-performance liquid chromatography. Res Commun Mol Pathol Pharmacol 1997; 98: 313-324.
12. Shin WG, Lee MG, Lee MH, Kim ND. Factors influencing the protein binding of vancomycin. Biopharm Drug Disposit 1991; 12: 637-646.
13. Lui CY, Chiou WL. pH and volume shifts during equilibrium dialysis. Biopharm Drug Disposit 1986; 7: 309-314.
14. Øie S, Guentert TW. Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer. J Pharm Sci 1982; 71: 127-128.
15. Lévai F, Szatmári I. The pharmacokinetics of ipriflavone. Acta Pharm Hung 1995; 65: 219-222.
16. Lee SH, Lee MG. Factors influencing the protein binding of azosemide using an equilibrium dialysis technique. Biopharm Drug Disposit 1995; 16: 615-626.
17. Mackchan JJ. Influence of protein binding and use of unbound (free) drug concentration. In Evans WE, Schentag JJ, Jusko WJ (eds) Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring, 3rd edition. Vancouver, WA: Applied Therapeutics, 1992; 5-1-5-48.
18. Shim HJ, Lee MG, Lee MH. Factors influencing the protein binding of bumetanide using an equilibrium dialysis technique. J Clin Pharm Ther 1991; 16: 467-476.
19. Prandota J, Pruitt AW. Furosemide binding to human albumin and plasma of nephrotic syndrome. Clin Pharmacol Ther 1975; 17: 159-166.